Type II diabetes

A phase I double-blind placebo-controlled clinical trial examined the effects of a 10:1 CBD/THC sublingual spray in improving glycemic control and lipid profiles in patients with Type II Diabetes. The study involved 50 patients, 25 of whom were given a 200 mg/20 mg CBD/Δ9-THC sublingual spray twice daily for eight weeks, while the other 25 were given a placebo. The study found that the active treatment arm showed significant improvements in various biomarkers related to cardiovascular health and glucose metabolism. The results suggest that adjunctive treatment with sublingual CBD/Δ9-THC can improve glycemic control and lipid profiles in patients with Type II Diabetes.